Patents Assigned to SDF BioPharma Inc.
  • Methods for reducing elevated glucose levels
    Patent number: 11981928
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: May 14, 2024
    Assignee: SDF BIOPHARMA INC.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Genetically modified stem cells
    Patent number: 11739298
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: November 9, 2021
    Date of Patent: August 29, 2023
    Assignee: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • GENETICALLY MODIFIED STEM CELLS
    Publication number: 20220145262
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: November 9, 2021
    Publication date: May 12, 2022
    Applicant: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Genetically modified stem cells
    Patent number: 11186827
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: November 30, 2021
    Assignee: SDF BIOPHARMA INC.
    Inventors: Gerald F. Swiss, David Kiewlich
  • GENETICALLY MODIFIED STEM CELLS
    Publication number: 20210355449
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Application
    Filed: April 5, 2021
    Publication date: November 18, 2021
    Applicant: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich
  • Genetically modified stem cells
    Patent number: 10982190
    Abstract: Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: April 20, 2021
    Assignee: SDF BioPharma Inc.
    Inventors: Gerald F. Swiss, David Kiewlich